Drugs / CD371-specific/YSNVz/I-18 CAR T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06017258 | Sep 2023 → Dec 2026 expected | acute myeloid leukemia | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD371-specific/YSNVz/I-18 CAR T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06017258 ↗ |
| Action | Deplete | “This pilot study highlights the activity of low-dose IL-18 "armored" CAR T cells against refractory AML and their potential to promote CAR T-cell cytotoxicity and innate...” PMID 40864984 ↗ Dec 2025 |
| Modality | Cell therapy | “CD371/SAVVY/IL-18 CAR T cells” PMID 40864984 ↗ Dec 2025 |
| Target | CLEC12A | “Phase I Trial of CLEc12a (CD371) Targeted ArmoRed Immune Effector Cells” NCT06017258 ↗ |